Investors Can Join Class Action Against REGENXBIO Inc. for Securities Fraud

Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit

The Schall Law Firm, a recognized firm specializing in shareholder rights litigation, is drawing attention to an emerging class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX). This case highlights violations of key sections of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a) and Rule 10b-5 as promulgated by the U.S. Securities and Exchange Commission.

Understanding the Case

This class action pertains to investors who acquired REGENXBIO securities during a defined period from February 9, 2022, to January 27, 2026. Allegations suggest that the company made several false and misleading statements concerning its product candidate RGX-111, which apparently concealed negative information regarding its efficacy and safety profile. These misrepresentations ultimately resulted in financial damages for the investors when the truth surfaced, revealing the existence of a serious intraventricular CNS tumor in a participant involved in the RGX-111 study.

Importance of Legal Action

For those who suffered losses due to these events, this lawsuit presents a chance to recover damages. Shareholders are encouraged to contact the Schall Law Firm before April 14, 2026, to discuss their options and potentially join the class. The firm is offering free consultations to anyone affected and is advocating for the rights of investors globally.

Brian Schall, the lead attorney at Schall Law Firm, emphasizes the need for shareholders to act promptly. Without taking action, they may become absent class members and lose their rights to recovery.

The Implications for REGENXBIO Inc.

The revelations surrounding REGENXBIO have significant implications, especially as the company had previously painted a positive outlook regarding its products while hiding critical safety data. Once this information came to light, it triggered a drop in investor confidence and market valuation. Investors must be vigilant about the statements made by companies they invest in and remain aware of potential red flags, such as withholding crucial safety data.

Next Steps for Investors

Those interested in participating in the lawsuit should reach out to the Schall Law Firm at 2049 Century Park East, Suite 2460, Los Angeles, CA, or by calling 310-301-3335. Individuals can also visit their website at www.schallfirm.com for more information and to formally express their intention to participate in the class action.

Investors should be aware that the class has not yet received certification, and until this process is complete, they are not officially represented by legal counsel. Nevertheless, the firm specializes in securities class action cases and has established experience dealing with complex investor rights issues.

Conclusion

The ongoing situation with REGENXBIO Inc. serves as a critical reminder of the importance of transparency in corporate communications. Investors are advised to keep abreast of legal proceedings and to consider their rights seriously when engaging in capital markets. The opportunity to join a class action lawsuit like this one can provide a means of accountability for companies that may mislead their stakeholders.